Products
Oberotatug Biosimilar Monoclonal Antibody (CD205) for Research
Cat No.: GMP-Bios-INN-1305
Anti-LY75/CD205/DEC205 therapeutic antibody (Pre-made Oberotatug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Oberotatug (development codes MEN1309/OBT076) is a monoclonal antibody targeting LY75 (DEC-205). It is developed by Agenus, Menarini, and Oxford BioTherapeutics for adenoid cystic carcinoma and solid tumors. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1305-1mg | 1mg | 3090 |
| GMP-Bios-INN-1305-10mg | 10mg | |
| GMP-Bios-INN-1305-100mg | 100mg | |
| GMP-Bios-INN-1305-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Oberotatug biosimilar, Whole mAb, Anti-LY75/CD205/DEC205 Antibody: Anti-LY75/CD205/Lymphocyte antigen 75/Ly-75 therapeutic antibody |
| INN Name | Oberotatug |
| Target | LY75/CD205/DEC205 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Agenus;Groupe Oncologie Radiotherapie Tete et Cou;Menarini;Oxford BioTherapeutics |
| Conditions Approved | na |
| Conditions Active | Adenoid cystic carcinoma;Solid tumours;Cancer |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
